| Candel Therapeutics is a clinical stage biopharmaceutical company. Through its subsidiaries, Co. is engaged in the development and commercialization of cancer immunotherapy drugs. Co. offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Co.'s product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, prostate cancer and therapy for pancreatic cancer; and CAN-3110. We show 2 historical shares outstanding datapoints in our CADL shares outstanding history coverage, used to compute CADL market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CADL market cap history over the course of time is important for investors
interested in comparing CADL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CADL versus a peer is one thing; comparing
CADL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CADL can fluctuate over the course of history.
With this page we aim to empower investors researching CADL by allowing them to research the CADL market cap history.